Nature Communications
Home Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors
Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Article Type: Correction Article History
Table of Contents
Iketani,Forouhar,Liu,Hong,Lin,Nair,Zask,Huang,Xing,Stockwell,Chavez,and Ho: Author Correction: Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors

Correction to: Nature Communications 10.1038/s41467-021-22362-2, published online 1 April 2021.

The original version of this Article omitted the following from the Acknowledgements: Part of the research was conducted at the Northeastern Collaborative Access Team beamlines, which are funded by the National Institute of General Medical Sciences from the National Institutes of Health (P30 GM124165). This has now been corrected in both the PDF and HTML versions of the Article.